Description: Xeris Pharmaceuticals Inc is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations.
Home Page: www.xerispharma.com
XERS Technical Analysis
180 North LaSalle Street
Chicago,
IL
60601
United States
Phone:
844 445 5704
Officers
Name | Title |
---|---|
Mr. Paul R. Edick | Chairman & CEO |
Mr. John P. Shannon | Pres & COO |
Ms. Beth P. Hecht J.D. | Chief Legal Officer & Corp. Sec. |
Dr. Steven J. Prestrelski MBA, Ph.D. | Co-Founder & Chief Scientific Officer |
Mr. Steven M. Pieper | Chief Financial Officer |
Ms. Allison Wey | Sr. VP of Investor Relations & Corp. Communications |
Dr. Kenneth E. Johnson Pharm. D., Pharm.D. | Sr. VP of Global Devel. & Medical Affairs |
Mr. Kevin McCulloch | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 3.4095 |
Price-to-Sales TTM: | 1.8493 |
IPO Date: | 2018-06-21 |
Fiscal Year End: | December |
Full Time Employees: | 294 |